natgillin/translations-raw huggingface dataset:
Another particular embodiment of the invention is the aqueous pharmaceutical suspension, wherein the particle size is less than about 50 um; or more particularly 40 um; for at least about 90% of the fexofenadine zwitterionic dihydrate Form I. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 1, naznačena time što veličina čestica je manja od otprilike 50 mm za najmanje otprilike 90 % dvojnoionskog dihidratnog Oblika I feksofenadina.
In one embodiment, the progeny T cells in the human comprise a memory T cell. In one embodiment, the T cell is an autologous T cell. 
T stanica za upotrebu prema patentnom zahtjevu 10, naznačena time što potomstvo T stanica u čovjeku sadrži memorijsku T stanicu.
In an embodiment the mixture prepared in STEP C is further seeded with previously prepared crystals of the desired polymorph of the compound of formula (I-S). 
KORAK D: hlađenje smjese pripremljene u KORAKU C; da se dobije talog spoja formule (I-S).
and with sodium hydroxide to give a compound of the formula (XV) 
CH.SO,y (XIV) i reagira s natrijevim hidroksidom da se dobije spoj s formulom (XV) F a.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for use according to any one of claims 24 to 29, wherein the method comprises administration of one or more further therapeutic agents to the subject. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevima 16 do 21, naznačeno time što metoda uključuje primjenu jednog ili više daljnjih terapijskih sredstava subjektu.
The compound or pharmaceutically acceptable salt thereof for use according to claim 11, wherein the disease or disorder is selected from Alzheimer's disease, bipolar disorder, pain, Parkinson's disease, and schizophrenia. 
Spoj ili farmaceutski prihvatljiva sol tog spoja za primjenu u skladu sa patentnim zahtjevom 11, pri čemu bolest 1li poremećaj je odabran od Alzheimerove-ove bolesti, bipolarnog poremećaja, boli, Parkinsonove bolesti, i šizofrenije.
The pyridone derivative, or a salt thereof, according to (8), wherein R4 in the formula (I) represents a methyl group. 
Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 4, naznačen time da je R* u formuli (I) atom vodika, atom fluora ili metil grupa.
A combination consisting essentially of the B-lactamase inhibitor: or a pharmaceutically acceptable salt thereof, and sulbactam, or a pharmaceutically acceptable salt thereof. 
Kombinacija koja se u osnovi sastoji od inhibitora B-laktamaze: ili njegove farmaceutski prihvatljive soli i sulbaktama, ili njegove farmaceutski prihvatljive soli.
or R1 and R2 form a 3- to 6-membered carbocyclic ring; or R2 and R3 form a 3- to 6-membered carbocyclic ring; 
ili R2 i R3 oblikuju karbociklični ili arilni prsten sa 3 do 6 članova ili heterociklični ili heteroarilni prsten sa 3 do 6 članova;
A dihydrospiro-[cycloalkylamine]-pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1 or 2, wherein R1 represents an unsubstituted 4-pyridinyl group or unsubstituted 4-pyrimidinyl group. 
Dihidrospiro[cikloalkilamin|pirimidonski derivat, ili njegova sol, ili njen solvat ili hidrat, prema patentnom zahtjevu 1 ili 2, naznačen time što R1 predstavlja nesupstituiranu 4-piridinilnu skupinu ili nesupstituiranu 4- pirimidinilnu skupinu.
determining (56) said operational parameters from said matched estimated torque-speed transfer function and said computed torque-speed transfer function. 
- određivanje (56) navedenih radnih parametara iz navedene uspoređene procijenjene funkcije prijenosa okretnog momenta u brzinu i navedene izračunate funkcije prijenosa okretnog momenta u brzinu.
The pharmaceutical composition of claim 1, wherein the catechol-O-methyltransferase inhibiting compounds are selected from the group consisting of entacapone, tolcapone, nitecapone, and combinations thereof. 
Farmaceutski sastav, prema zahtjevu 1, naznačen je time da su u njemu inhibirajući spojevi katekol-O-metiltransferaze odabrani iz grupe koja se sastoji od entakapona, tolkapona, nitekapona i njihovih kombinacija.
or a pharmaceutically acceptable salt or inner salt thereof. 
FI SN ili njihove farmaceutski prihvatljivo soli ili unutarnje soli.
The blister pack according to Claim 8, in which said top layer (6) comprises at least other two layers (6B, 6C) located on opposite sides of said aluminium layer (6A). 
. Blister pakiranje prema 8., naznačeno time da navedeni gornji sloj (6) sadrži najmanje još dva sloja (6p, 6c) koji se nalaze na suprotnim stranama navedenog aluminijskog sloja (6).
The method according to claim 17 wherein the hypolipemiant agent is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, fluvastatin, eptastatin, lifibrol, acifran, acitemate, flunicate and rosuvastatin. 
Upotreba prema bilo kojem zahtjevu 18 do 29, naznačena time, da farmaceutski sastav nadalje sadrži hipolipemijantno sredstvo, ponajprije simvastatin, lovastatin, atorvastatin, pravastatin, fluvastatin, eptastatin, lifibrol, acifran, acitemat, glunikat ili rosuvastatin.
In an embodiment, the human engineered CGRP antibody comprises two light chains and two heavy chains wherein each LC amino acid sequence is SEQ ID NO: 29 and each HC amino acid sequence is SEQ ID NO: 34. 
Ljudsko konstruirano protutijelo protiv CGRP u skladu s patentnim zahtjevom 1, naznačeno time što je aminokiselinski slijed navedenog LCVR SEQ ID NO: 19, a aminokiselinski slijed navedenog HCVR je SEQ ID NO: 24.
the second fusion protein is SEQ ID NO:3 or an amino acid sequence that is at least 95% identical to SEQ ID NO:3. 
(b) drugi fuzijski protein je SEQ ID NO:3 ili aminokiselina koja je najmanje 95% identična sa SEQ ID NO:3.
In this case there is shown a ground floor 15, a storey floor 16 and a roof floor 17. 
U ovom slučaju prikazano je prizemlje 15, prvi kat 16 i potkrovlje 17.
A pharmaceutical composition according to any one of claims 1 to 9, further comprising: water-for-injection, aqueous saline solution, aqueous glucose solution, saline for injection/infusion, glucose for injection/infusion, Ringer's solution, or lactated Ringer's solution. 
Farmaceutski sastav prema zahtjevu 11 ili 12, naznačen time, da nadalje sadrži: vodu za injekciju, vodenu solnu otopinu, vodenu otopinu glukoze, vodenu otopinu soli za injekciju/infuziju, glukozu za injekciju/infuziju, Ringer-ovu otopinu, ili mliječnu Ringer-ovu otopinu.
In a second aspect, this invention is pharmaceutical compositions comprising compounds of the first aspect of this invention, and optionally one or more excipients. 
U drugom aspektu, ovaj izum je farmaceutski sastav koji sadrži spojeve prvog aspekta ovog izuma, i po izboru jedan ili više ekscipijenasa.
any of claim 6 to 9. 
bilo kojem od zahtjeva 4 do 6.
#27. A method according to aspect #26, wherein the solvent system of the inner coating preparation is aqueous. 
Postupak za koji se traži zaštita patenta u patentnom zahtjevu 11, pri čemu je sustav otapala unutarnjeg pripravka za oblaganje vodik.
The antibody or antigen-binding fragment or pharmaceutical composition for use according to any one of claims 4 to 6, wherein the use in medicine is the use in a method for the treatment of palmoplantar pustulosis or generalized pustular psoriasis. 
Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 8, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja generalizirane pustularne psorijaze.
ring A is optionally substituted with 1 or 2 independent occurrences of R5, wherein R5 on ring A, when present, is selected from halo or optionally substituted C1-4 aliphatic; and 
prsten A je izborno supstituiran sa 1 ili 2 nezavisna R5, pri čemu je R5 na prstenu A, kada je prisutan, izabran od halo ili izborno supstituiranog C1-4 alifatika; i
hydrogen, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, hydroxy, lower alkoxy, carboxy, lower alcoxycarbonyl, acyl, nitro, carbamoyl, lower alkylaminocarbonyl, -NR5R6, wherein R5 and R6 are each independently selected from hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted lower alkylaminocarbonyl, substituted or unsubstituted lower arylaminocarbonyl, alkoxycarbonyl, carbamoyl, acyl or R5 and R6 are combined with a nitrogen atom to form a heterocyclic group, 
vodik, halogen, supstituiran ili nesupstituiran niži alkil, supstituiran ili nesupstituiran niži alkenil, supstituiran ili nesupstituiran niži alkinil, hidroksi, niži alkoksi, karboksi, niži alkoksikarbonil, acil, nitro, karbamoil, niži alkilaminokarbonil, -NR5R6, gdje su i R5 i R6 nezavisno izabrani iz grupe koju čine vodik, supstituiran ili nesupstituiran niži alkil, supstituiran ili nesupstituiran niži alkenil, supstituiran ili nesupstituiran niži alkinil, supstituiran ili nesupstituiran aril, supstituiran ili nesupstituiran heteroaril, supstituiran ili nesupstituiran aralkil, supstituiran ili nesupstituiran niži alkilaminokarbonil, supstituiran ili nesupstituiran niži arilaminokarbonil, alkoksikarbonil, karbamoil, acil ili R5 i R6 su kombinirani sa atomom dušika tako da formiraju heterocikličnu grupu,
When the matrix is altered by disease or the nail surface is subject to trauma, this shine is lost. 
Kad se matriks promijeni uslijed bolesti ili je površina nokta podvrgnuta traumi, ovaj sjaj se gubi.
m represents 0 to 1 and o represents 1 to 2. 
m predstavlja 0 do 1; i o predstavlja 1 do 2.
Briefly, RBL cells stably transfected with human GnRH receptors are seeded in 24 well plates at a density of 200,000 cell/well for 24 hrs. 
Ukratko, RBL stanice stabilno transficirane ljudskim receptorima GnRH nasađene su na ploče s 24 jažica, u gustoći od 200.000 stanica po jažici, u trajanju od 24 sata.
PCT/CN2014/073068, filed Mar. 7, 2014, International Application No. 
(31) Broj prve prijave: PCT/CN2014/073068 (32) Datum podnošenja prve prijave: 07.03.2014.
The cyclohexenone compound as claimed in claim 22, wherein the prostate cancer cells are from LNCaP or DU145 cell line. 
Cikloheksenonski spoj prema patentnom zahtjevu 22, naznačen time, da su stanice karcinoma prostate iz LNCaP ili DU145 stanično linije.
oxooxazolidinyl, said oxooxazolidinyl being unsubstituted or substituted once or twice by C1-6alkyl; 
oksooksazolidinil, pri čemu je navedeni oksooksazolidinil nesupstituiran ili supstituiran jednom ili dva puta s C1−6alkilom;
Then, the amount of sucrose or lactose (55 g sucrose formulation A and B, and 27.5 g lactose formulation F) was added and the mixture was stirred for an additional period of approximately 1h until dissolution. 
Zatim, količina saharoze ili laktoze (55 g saharoze oblika A i B, i 27.5 g laktoze oblika F) je dodana i smjesa je miješana za dodatni period od približno 1 sat do otapanja.
administration of two or more consecutive doses of the fusion protein administered using a therapeutically effective dose regimen to a subject results in a prolonged period between consecutive Cmax peaks and/or Cmin troughs for blood levels of the fusion protein compared to the corresponding GH that lacks the XTEN and administered using a therapeutically effective dose regimen established for the GH; or 
(ii) - primjena dvije ili više uzastopnih doza fuzijskog proteina koji se primjenjuje na pojedincu koristeći terapeutski djelotvoran dozni režim, rezultira u produljenju perioda između uzastopnih vrijednosti razine fuzijskog proteina u krvi od najviše vrijednosti C,,x i/ili najniže vrijednosti Cy;,, U usporedbi s odgovarajućim GH kojemu nedostaje XTEN 1 koji se primjenjuje korištenjem jednog terapeutski djelotvornog doznog režima ustanovljenog za GH; ili
B is (CH2)n where n is an integer ranging from 0-10, or B is an unsaturated carbon chain of 2-10 carbons; and 
B je (CH>), gdje je n cijeli broj u rasponu od 0-10, ili je B nezasićemi lanac ugljika s 2-10 ugljika; i
wherein the exit temperature of the drying medium has a temperature of 115 °C or less, 
(b) pri čemu izlazna temperatura medija za sušivanje ima temperaturu od 115 *C ili manje,
The method according to claim 1, wherein the treatment of posterior segment of eye diseases benefits from binding of somatostatin or somatostatin analogue to somatostatin receptors. 
Topikalna očna kompozicija u skladu sa zahtjevom 1, naznačena time što se tretman i/ili prevencija zasnivaju na vezivanju somatostatina ili analoga somatostatina za receptore somatostatina.
The rolling member as claimed in claim 7, wherein said rolling member is an agricultural wheel and the support is in the form of a wheel rim around which the at least one tire is mounted. 
Valjak u skladu s bilo kojim patentnim zahtjevom 8 ili 9, naznačen time, da je nosač (101) u obliku naplatka kotača (71) oko kojeg je montirana guma (1).
A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation which is cured at a temperature of at least about 60 °C for a time period of at least about 1 minute, the extended release matrix formulation comprising a composition comprising at least: at least one active agent selected from opioid analgesics; 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem koji sadrži formulaciju matrice sa produljenim otpuštanjem koji je stvrdnut na temperaturi od najmanje oko 60 "C tijekom vremenskog perioda od najmanje oko 1 minute, te formulacija matrice s produljenim otpuštanjem sadrži pripravak koji je naznačen time da sadrži barem: (1) najmanje jedno aktivno sredstvo koje je odabrano od opioidnih analgetika;
A method according to claim 1, wherein said pathological state is a mood disorder selected from the group consisting of a bipolar disorder and a depressive disorder. 
H-inđazol-3-karboksamid za uporabu prema zahtjevu 12, naznačen time, da su navedeni poremećaji raspoloženja, odabrani iz skupine koju čine bipolarni poremećaji i depresivni poremećaji.
The method of claim 1, wherein the target cell expressing human PSMA is a tumor cell. 
2, 4, 6 i 8, a druga vežuća domena se bira iz skupine koju čine:
a compound having a structure of Formula or stereoisomer thereof or pharmaceutically acceptable salt thereof: wherein: 
HR P20160478 T1 tvar koja ima strukturu Formule ili njenog stereoizomera ili njene farmaceutski prihvatljive soli: pri čemu
The composition of claim 4, wherein the sorbitol and natural gum are in a weight ratio of 1.6:1 to 5:1. 
Kompozicija prema zahtjevu 3, pri čemu su sorbitol i prirodna guma u težinskom odnosu od 1.6:1 do 5:1, a prvenstveno 1.8:1 do 3:1.
Method according to any of the preceding claims, further involving the step: compacting said filling material, if needed, using a compactor arranged for the width of said micro trench and the depth of said first layer (L1); wherein said compacting is performed before said sealing step. 
Postupak prema bilo kojem od prethodnih zahtjeva, nadalje obuhvaćajući korak: kompaktiranja navedenog materijala za punjenje, ako je potrebno, upotrebom kompaktora raspoređenog za širinu navedenog mikro-rova i dubinu navedenog prvog sloja (L1); naznačeno time da se navedeno kompaktiranje izvodi prije navedenog koraka brtvljenja.
An immunogenic composition comprising an M72 related antigen, wherein the M72 related antigen comprises a sequence having at least 90% identity to SEQ ID No: 1, the pH of said composition is in the range 7.0 to 9.0, and the conductivity of the composition is 5 mS/cm or lower. 
Imunogeni pripravak, naznačen time što sadrži antigen srodan M72, naznačen time što antigen srodan M72 sadrži slijed najmanje 90% istovjetan SEQ ID NO: 1, pH navedenog pripravka je u rasponu od 7,5 do 8,5, a koncentracija natrijevog klorida je 50 mM ili niža.
contacting the sample with an anti-SDMA antibody conjugated to a label and with an SDMA analog; wherein the anti-SDMA antibody is specific for free SDMA and has no or substantially no cross-reactivity with one or more compounds selected from the group consisting of asymmetrical dimethylarginine (ADMA), L- arginine, and N-methylarginine and detecting the presence or amount of the label associated with the SDMA analog, thereby determining the presence or amount of SDMA in the sample. 
kontaktiranje uzorka s anti-SDMA antitijelom konjugiranim na etiketu i sa SDMA analogom; pri čemu anti-SDMA antitijelo je specifično za slobodnu SDMA i nema ili bitno nema unakrsnu reaktivnost s jednim ili više spojeva odabranih iz skupine koja se sastoji od asimetričnog dimetilarginina (ADMA), L-arginina, i N-metilarginina i otkrivanje prisutnosti ili količine oznake povezane s SDMA analogom, te se na taj način određuje prisutnost ili količina SDMA u uzorku.
The method of claim 1, wherein the solution comprises a levofloxacin or ofloxacin concentration from about 90 mg/ml to about 110 mg/ml, a magnesium chloride concentration from about 175 mM to about 225 mM, a pH from about 5 to about 7; an osmolarity from about 300 mOsmol/kg to about 500 mOsmol/kg, and lacks lactose. 
Aerosol za uporabu sukladno patentnom zahtjevu 1, pri čemu se otopina u osnovi sastoji od koncentracije levofloksacina od 90 mg/ml do 110 mg/ml, koncentracije magnezij klorida od 180 mM do 220 mM, pH od 5 do 7, osmolalnosti od 300 mOsmol/kg do 500 mOsmol/kg, i nedostaje mu laktoza.
In a further aspect described herein, the compound of Formula 4 is hydrolyzed using a hydrolyzing agent in the presence of a solvent. 
s reagensom koji može uzrokovati da se zaštitna skupina veže za fenolni kisik spoja koji s formulom 6 u prisutnosti otapala.
The pharmaceutical composition of claim 10, wherein the anti-tumor agent is an anti-tumor antibody. 
Farmaceutski pripravak prema zahtjevu 14, naznačen time da anti-tumorsko sredstvo je anti-tumorsko protutijelo.
In an embodiment of the method according to the invention, into the impregnating chamber is blown before starting the pressure stage compressed air heated to a temperature of over 50° C. so that the pressure of the impregnating chamber increases above normal pressure. 
Postupak sukladno Zahtjevu 6, naznačen time što je u impregnacijsku komoru (1) prije započinjanja faze pritiska upuhan komprimirani zrak zagrijan na temperaturu višu od 50%C na način da se pritisak u impregnacijskoj komori podigne iznad normalnog pritiska.
In the first place, the user places a suitable vessel, i.e. 
Korisnik najprije stavlja odgovarajuću posudu, tj.
Once the initial acid gas evolution had ceased the mixture was basified (ca. pH 12) using solid sodium carbonate. 
Jednom kad prestane inicijalno razvijanje plina kiseline, smjesa se zalužni pomoću krutog natrij karbonata (oko pH 12).
Another aspect of the invention is stereoisomer of formula I according to formula Ia. 
aalkiDpiperazinil, morfolinil, ili homopiperidinil; ili njegova farmaceutski prikladna sol.
In another embodiment, the present invention includes a pharmaceutical composition comprising a compound of formula I or I(a) and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 1 1 farmaceutski prihvatljiv nosač.
The method of claim 1, wherein the cumulative total amount of phosphorous per unit volume in said medium is greater than 5 mM. 
Postupak prema Zahtjevu 1, što je kumulativna ukupna količina fosfora po jedinici volumena u spomenutom mediju veća od približno 5 mM.
The method of E 41, wherein the monoclonal antibody or monoclonal antibody fragment binds to and inhibits the activity of IL-23p19. 
Antagonist za uporabu u skladu sa zahtjevom 41, naznačen time, da se monoklonsko antitijelo ili fragment monoklonskog antitijela veže na i inhibira djelovanje IL-23p19.
a sequence of amino acids that is at least 80% identical to a heavy chain variable domain sequence of H5; 
slijed aminokiselina najmanje 80% identičan slijedu SEQ ID NO:361; di.
The pharmaceutical composition of claim 1, further comprising at least one pharmaceutically acceptable adjuvant, excipient, or carrier. 
Formulacija cjepiva prema zahtjevu 1 ili 2, naznačena time, da formulacija obuhvaća dodatno najmanje jedan farmaceutski prikladan adjuvant, pomoćno sredstvo i/ili nosač.
Images of aortas stained with Red oil and hematosiline eosin were taken with a standard camera. 
Slike aorti obojenih s Red Oil i hematosilin eozinom su napravljene standardnom HR P20090152 T3 kamerom.
Pharmaceutical composition according to claim 4 or 5, wherein said microparticles of said first formulation, or of said second formulation, or of both formulations, are microspheres. 
Farmaceutski pripravak prema zahtjevu 1 ili 2, gdje su te mikročestice prve skupine, ili druge skupine, ili obje skupine, mikrosfere.
vi) According to another variant of the invention, the compounds of formula I as defined in embodiment i), ii) or iii) above, or their pharmaceutically acceptable salts, will be such that R3 represents heteroaryl-(C1-C4)alkyl. 
Uporaba prema jednom od zahtjeva 1 do 3, naznačena time, da je spoj formule Ia ili njegova farmaceutski prihvatljiva sol takav/takva da R> predstavlja heteroaril-(C,-Cx)alkil.
The process according to claim 7, wherein one aliphatic carboxylic acid is stearic acid and the other one is selected from the group consisting of octanoic acid, myristic acid, palmitic acid, arachidic acid, behenic acid and lignoceric acid. 
Postupak prema zahtjevu 6, naznačen time da jedna alifatska karboksilna kiselina je stearinska kiselina i druga je odabrana iz skupine koju čine oktanska kiselina, miristinska kiselina, palmitinska kiselina, arahidska kiselina, behenska kiselina i lignocerinska kiselina.
An isolated host cell comprising the nucleic acid molecule of claim 8 or the expression vector of claim 9, wherein the host cell is preferably a mammalian cell or an insect cell. 
Izolirana stanica domaćin naznačena time da sadrži molekulu nukleinske kiseline prema zahtjevu 13 ili ekspresijski vektor prema zahtjevu 14, pri čemu, poželjno, stanica domaćin je stanica sisavca ili stanica insekta.
A compound according to claim 1, wherein X represents S, Y represents O, L represents C1 to 3 alkylene, substituted with C1 to 6 alkoxy and R1 represents hydrogen. 
Spoj prema zahtjevu 1, naznačen time da X predstavlja S, Y predstavlja O, L predstavlja C 1 do 3 alkilen, supstituiran sa C 1 do 6 alkoksi i R1 predstavlja vodik.
The pharmaceutical composition of claim 1, wherein the second lipid nanoparticle comprises an mRNA that is (i) identical to the mRNA in the first lipid nanoparticle or (ii) not identical to the mRNA in the first lipid nanoparticle. 
Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time da druga lipidna nanočestica sadrži RNK koja je (1) identična iRNK u prvoj lipidnoj nanočestici ili (11) nije identična iRNK u prvoj lipidnoj nanočestici.
at least one sugar and/or at least one sugar alcohol, characterised in that a major proportion of component (ii) consists of: 
(1) najmanje jedan šećer i/ili najmanje jedan šećerni alkohol, za koji je karakteristično da se glavna komponenta komponente (ii) sastoji od:
Preferably, the agents to be used in accordance with embodiments of the present invention are provided in a stabilized form. 
Sredstvo sukladno bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time da je netolerancija fruktoze petoterancija crijevne fruktoze.
The composition of claim 1 or 2 wherein the microparticles have an average diameter of 0.01 µm - 100 µm, preferably 0.01 µm - 50 µm. 
Smjesa iz patentnog zahtjeva 1 ili 2, naznačena time, da mikročestice imaju prosječni promjer od 0,01 um - 100 jim, poželjno je od 0,01 um - 50 um.
Typically, the ambient temperature is within a range of about 15° C. to about 30° C. 
Tipično, ambijentalna temperatura je unutar raspona od 15 "C pa do 30 "C.